Towards the formation of a positronium coherent beam

Positronium (Ps) has emerged as a promising test particle within the QUPLAS collaboration for investigating the gravitational effect. In this work, we present a novel approach to generate a monoenergetic and highly coherent Ps beam by creating a negative Ps ion (Ps$^-$, consisting of two electrons and one positron). The necessary positron beam is formed by using a high flux electron LINAC. Subsequently, we utilize a Fabry-Perot IR laser cavity operating at a wavelength of 1560 nm to selectively remove the extra electron. An alternative pulsed laser operating at a 3600 nm wavelength was studied to reduce broadening due to recoil and excitation. Here, we provide a Monte Carlo simulation to estimate the characteristics of the Ps beam, including its energy distribution and intensity profiles. The results obtained from this study will provide essential groundwork for future advancements in fundamental studies as Ps gravity measurements by using a Mach-Zehnder interferometer.Comment: 16 pages, 4 figure

A large-momentum-transfer matter-wave interferometer to measure the effect of gravity on positronium

This paper reports the study of a new interferometric configuration to measure the effect of gravity on positronium. A Mach–Zehnder matter-wave interferometer has been designed to operate with single-photon transitions and to transfer high momentum to a 200 eV positronium beam. The work shows the results and methods used to simulate the interferometer and estimate the operating parameters and the time needed to perform the experiment. It has been estimated that within less than 1 year, the acquisition time is sufficient to achieve a 10% accuracy level in measuring positronium gravitational acceleration, even with a poorly collimated beam, which is significant for theoretical models describing matter–antimatter symmetry. These results pave the way for single photon transition large momentum transfer interferometry with fast atomic beams, which is particularly useful for studies with antimatter and unstable atoms

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort.

BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. METHODS: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. RESULTS: SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced ≥1 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with ≥1 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not ≥5. CONCLUSIONS: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginterferon alfa-2a/ribavirin.This study was sponsored by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Support for third-party writing assistance for this manuscript, furnished by Blair Jarvis MSc, ELS, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA <50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was identified by a baseline scoring system (range: 0-9 points) on which scores of 5 to 9 and <5 represent high and low probability of SVR24, respectively. Results: SVR24 rates were 46.1 % (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/396), respectively, in G1,2, 3, and 4 patients. Overall, 16.9% and 21.8% patients experienced 651 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/pulmonary disease, and low hematological indices were prognostic factors of sr-RD; SVR24 was lower in patients with 651 vs. no sr-RD by Week 4 (37.9% vs. 54.4%; P = 0.0046) and Week 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD by Week 4/12 significantly reduced SVR24 in patients with scores <5 but not 655. Conclusions: In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help select patients with a high probability of SVR24 and a low probability of sr-RD with peginter-feron alfa-2a/ribavirin

Editorial

Manufacturers and organisations of all kinds are re-thinking how they operate as they strive to compete in today\u2019s rapidly changing global, business environment. Increasingly, companies are deciding to join networks and to establish various forms of co-operation in order to gain access to information, skills and capabilities that can be combined and exploited successfully in the marketplace. This trend challenges the traditional models of operations management which tend to focus on individual companies. The concept of Supply Chain Management (SCM) has emerged to indicate a process-oriented, inter-organisational approach to procuring, manufacturing and delivering both products and services. The co-ordination and integration of decision making within such activities has been identified as a main element in cost reduction but customer services are kept and even enhanced, i.e. there is a shift in the classical trade-offs between costs and services. Nowadays, under the pressure of global marketplaces and the impetus and stimulation offered by internet and IT opportunities, the concept of SCM has enriched its content and enlarged its borders, evolving from its role as merely a logistics perspective. SCM is now making itself felt within several inter-organisational business processes, such as customer relationship management, demand management, order fulfilment, product development and commercialisation and so on, and has become a strategic concept and the paradigm of various business models in the emerging web economy

Real-time monitoring of a positron beam using a microchannel plate in single-particle mode

This work presents a real-time diagnostic method to monitor and characterize a positron beam by using a microchannel plate (MCP), a phosphor screen and a CCD camera. We propose a digitizing method based on single-particle detection. This approach offers the possibility to quantify the particles per unit time that interact with the MCP. This type of detector is based on a consolidated technology and its efficiency has been demonstrated for nuclear radiation and particles in many experiments. This work also presents the detection efficiency as a function of the positron kinetic energy in the range from 50 eV to 17 keV, essential for a complete characterization of the particle beam. The method allows the characterization of a positron beam in real time with a spatial resolution of the order of tens of microns